Preclinical studies - employing CRISPR-based screens, phosphoproteomics, and patient-derived models - have consistently demonstrated that FAK inhibition in this context induces apoptosis and suppresses tumor growth (44, 51, 52). Here, PTK2 is linked to neoplasm.